Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
and strength and depth in oncology
3 INNOVATION
Selected assets, nearly all with exclusivity into 2030+
Solid Tumors
New for Q4
Hematology
Asset
KisqaliⓇ
Indication
Peak Sales
Next Milestone/ Status
Submission
Asset
Indication
Peak Sales
Next Milestone/ Status
Submission
HR+/HER2- BC (adj)
Ph3 NATALEE readout event- 2023
driven, expected end 20221
Canakinumab NSCLC adjuvant
Lu-PSMA-617 mCRPC post-taxane
mCRPC pre-taxane
in 2022
Ph3 CANOPY-A readout
2023
ScemblixⓇ
(asciminib)
Iptacopan²
CML 3L
CML 1L
PNH
aHUS
US approved
Ph3 ongoing
2025
Readout in 2022 (APPLY-PNH)
2023
Ph3 ongoing
2025
In registration
Sabatolimab
HR-MDS
Ph3 PSMAfore readout
2023
Ph2 STIMULUS-MDS-1
continues to PFS readout³
2022/2023
event-driven, end 20221
JDQ443
KRAS inhibitor
mHSPC
2/3L NSCLC (mono)
NSCLC (combo)
Ph3 PSMAddition ongoing
2024
AML
Ph3 STIMULUS-MDS-2 ongoing
Ph2 STIMULUS-AML-1 ongoing
2024
Ph3 start in H2 2022
Ph2 ongoing
2024
YTB323
2026+
CD19 CAR-T
Non-Hodgkin's
Lymphoma
Ph3 start 2022
2024
TNO155
SHP2 inhibitor
Solid tumors: multiple combinations being explored in ongoing trials
PHE885
Tislelizumab²
2L esophageal cancer
NSCLC
Other indications
Ociperlimab²
NSCLC
TIGIT mab
Other indications
In registration
H1 2022 EU submission,
2022
H2 2022 2L US submission
Ongoing trials
Ph3 ongoing4
BCMA CART-T
Multiple
myeloma
Ph2 start 2022
2024
Unprobabilized peak sales (USD): <1bn •• 1-2bn
... >2bn
'Wild Cards'
Ongoing trials4; additional
Ph3 study initiation H2 2022
NIS793 (mPDAC: Ph3 ongoing, colorectal cancer: Ph2 ongoing)
1. Could move to early 2023. 2. Peak sales potential based on all studied indications; Novartis territories. 3. Planned DMC readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or
OS outcomes of Ph2 and/or Ph3 trial. 4. Active trials are being conducted by BeiGene, option deal.
18 Investor Relations | Q4 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation